Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myeloid-derived growth factor (MYDGF)
- Target
- MYDGF
- Molecular classification
- Secreted growth factor-like protein, Other (novel cytokine-like protein not homologous to known growth factors or interleukins)
01
Overview
Myeloid-derived growth factor (MYDGF) is a novel, secreted, 142-amino-acid protein predominantly produced by bone marrow-derived monocytes and macrophages. It plays a key role in tissue repair, especially after cardiac injury, by promoting cell survival, angiogenesis, and anti-inflammatory responses. MYDGF is highly expressed in multiple tissues, notably oral epithelium and skin, and is implicated in cardiovascular repair, metabolic homeostasis, and modulation of inflammatory responses. Structural studies reveal it possesses a unique 10-stranded beta-sandwich fold distinct from classical growth factors or interleukins. It is an emerging therapeutic target for conditions requiring enhanced tissue regeneration, although clinical translation is limited by the protein's rapid clearance and incomplete functional characterization.
- Other names
- C19orf10R33729_1IL-25SF20IL-27EUROIMAGE1875335IL27wUPF0556 protein C19orf10interleukin 27 working designationstromal cell-derived growth factor SF20myeloid-derived growth factor
02
Mechanism of action
Endogenous or recombinant MYDGF acts by stimulating cardiac myocyte survival, promoting angiogenesis (via MAPK1/3, STAT3, CCND1 signaling), and inhibiting apoptosis (via PI3K/AKT pathway). Engineered PEGylated MYDGF acts via the same pathways but with extended half-life for therapeutic use.
03
Biological functions
Antiapoptotic activityCardiac protection and repair (especially after myocardial infarction)Tissue repair and regenerationPromotion of endothelial cell proliferation (angiogenesis)Regulation of cell apoptosis and proliferationAnti-inflammationGlycolipid metabolism regulation
04
Disease associations
Cardiovascular disease (e.g., myocardial infarction, atherosclerosis, heart failure)Metabolic disorderRenal diseaseAutoimmune/inflammatory disorderCancer
05
Safety considerations
Therapeutic challenges include short half-life of unmodified MYDGFNo significant safety concerns identified in current preclinical literature; lack of extensive clinical data
06
Interacting drugs
None (no approved drugs directly target MYDGF as of 2025; preclinical biologic approaches such as PEG-MYDGF are under investigation)
07
Biomarkers
None established or clinically validated for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Myeloid-derived growth factor (MYDGF).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myeloid-derived growth factor (MYDGF).